Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WellPoint Plans CER Guidance, Building On Progress With Outcomes Data

Executive Summary

WellPoint believes its discussions with drug manufacturers about patient outcomes have improved in the 18 months since it published technology assessment criteria focusing on that topic. Now it is updating its criteria to include how to submit results from comparative effectiveness research
Advertisement

Related Content

WellPoint's CER Guide Describes How It Will Determine Usefulness Of Studies
WellPoint's CER Guide Describes How It Will Determine Usefulness Of Studies
Senate Considers Revised Comparative Effectiveness Plan In Reform Bill
WellPoint CE Study Results In Coverage Adjustment For Oral Asthma Drugs
WellPoint Seeks More Quality Of Life, Cost Data In Formulary Submissions
WellPoint Seeks More Quality Of Life, Cost Data In Formulary Submissions

Topics

Advertisement
UsernamePublicRestriction

Register

PS052147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel